Silver Book Fact

Macugen to treat wet age-related macular degeneration (AMD)

A new FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)– pegaptanib sodium (Macugen)– reduced vision loss in 70% of clinical trial patients.

Gragoudas EA, Adamis AP, Cunningham ET, Feinsod M, Guyer DR. Pegaptanib for Neovascular Age-Related Macular Degeneration. NEJM. 2004; 351(27): 2805-16. http://content.nejm.org/cgi/content/abstract/351/27/2805

Reference

Title
Pegaptanib for Neovascular Age-Related Macular Degeneration
Publication
NEJM
Publication Date
2004
Authors
Gragoudas EA, Adamis AP, Cunningham ET, Feinsod M, Guyer DR
Volume & Issue
Volume 351, Issue 27
Pages
2805-16
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • DR Treatment Reduced Risk of Blindness
    Appropriate treatment can reduce the risk of blindness or moderate vision loss from DR by more than 90%.  
  • Cytokines in urine are associated with age-related macular degeneration (AMD) and could be developed as a biomarker and provide a practical tool for early detection  
  • The use of antioxidant vitamins and other new therapies for age-related macular degeneration (AMD) could reduce visual impairment and blindness from the disease by 35%.  
  • Treatment costs for a patient with early-stage glaucoma are about $2,000 less than those of a patient diagnosed with a later stage of the disease.  
  • DR Treatment Savings in the US
    Every year, the U.S. saves an estimated $1.6 billion by treating DR.